|Over a week ago |
Show Full Stories
XTo view all stories in expanded form, please subscribe.
Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations » 09:5805/1605/16/23
EXPE, RCL, WBD, NVCR, GILD, CBSH, PB, CFR, NEO, XBIO, CVNA, VOR, WAL, FHN, RYN
The most talked about and…
Vor Bio initiated with a Buy at JonesResearch » 17:1805/1505/15/23
JonesResearch analyst Justin Walsh initiated coverage of Vor Bio with a Buy rating and $18 price target. The company's lead clinical asset is trem-cel, a CD33-deletion eHSCT product being tested in acute myeloid leukemia, or AML, and its approach has the potential to substantially improve outcomes for AML patients seeking the only potentially curative therapy available, the analyst tells investors in a research note. Vor Bio is also well positioned to take advantage of, and participate in, the long-term trend of increasing numbers of allo-HSCT treatments performed on AML patients in the U.S., the firm added.
Vor Bio expects cash to fund operations into Q1 of 2025 » 16:1305/1105/11/23
Cash, cash equivalents…
Cash, cash equivalents and marketable securities were $210.2 million as of March 31, 2023, which is projected to fund operations into the first quarter of 2025.
Vor Bio reports Q1 EPS (43c), consensus (38c) » 16:1305/1105/11/23
"We are pleased with…
"We are pleased with the progress we made during the quarter. Our focus continues to be on actively enrolling and treating additional patients in our VBP101 study and submission of the VCAR33ALLO IND, which is on-track for the first half of 2023," said Dr. Robert Ang, Vor Bio's President and Chief Executive Officer. "We look forward to sharing additional data from VBP101 at EHA in June, initiating enrollment in VBP301, and treating our first patient with VCAR33ALLO once the IND clears."
|Over a month ago|
Vor Bio price target lowered to $10 from $15 at Barclays » 06:1403/2603/26/23
Barclays lowered the…
Barclays lowered the firm's price target on Vor Bio to $10 from $15 and keeps an Overweight rating on the shares. The firm said in a research note on Friday that the price target decrease reflects recent dilution and longer timelines to market given the pace of enrollment in the VOR33 study.
Vor Bio price target lowered to $16 from $17 at Stifel » 10:1203/2403/24/23
Stifel analyst Stephen…
Stifel analyst Stephen Willey lowered the firm's price target on Vor Bio to $16 from $17 and keeps a Buy rating on the shares following its Q4 earnings and corporate update. The recent disclosure of "encouraging" proof-of-concept data from the P1 VBP101 trial serves as a "significant de-risking event" for the asset and platform, the analyst tells investors. Further, the firm expects a number of incremental updates from this trial throughout FY23 to serve as a tailwind for the stock.
Vor Bio price target lowered to $22 from $38 at Baird » 06:3303/2403/24/23
Baird analyst Jack Allen…
Baird analyst Jack Allen lowered the firm's price target on Vor Bio to $22 from $38 and keeps an Outperform rating on the shares. The analyst said fundamentally we continue to have high conviction in Vor's scientific thesis; however, given the macroeconomic conditions we are reducing our price target to reflect the increased risk of dilution.
Vor Bio price target lowered to $17.50 from $20 at H.C. Wainwright » 06:1203/2403/24/23
H.C. Wainwright analyst…
H.C. Wainwright analyst Swayampakula Ramakanth lowered the firm's price target on Vor Bio to $17.50 from $20 and keeps a Buy rating on the shares post the Q4 results. Vor had approximately $230.2M in cash and cash equivalents, which is sufficient to fund planned operations into 2025, the analyst tells investors in a research note.
Vor Bio reports Q4 EPS (53c), consensus (60c) » 16:1803/2303/23/23
Cash, cash equivalents…
Cash, cash equivalents and investments were $230.2M as of December 31, 2022, which is projected to fund operations into the first quarter of 2025. "We are encouraged with the initial proof of concept demonstrated in patients treated in our VBP101 study," said Robert Ang, Vor Bio's president and CEO. "We remain focused on rapid enrollment and plan to share additional clinical data later this year. Our IND for VCAR33ALLO is on-track for submission in the first half of 2023 which, together with trem-cel, has the potential to transform outcomes for patients with blood cancers."
|Over a quarter ago|
Vor Bio presents clinical data from VBP101 Phase 1/2a study of trem-cel » 12:0302/1602/16/23
Vor Bio presented…
Vor Bio presented clinical data from VBP101, its Phase 1/2a multicenter, open-label, first-in-human study of trem-cel in patients with acute myeloid leukemia. In the first patient, trem-cel maintained hematopoiesis through three cycles of Mylotarg, which was well-tolerated at the initial dose level of 0.5 mg/m2. A second patient has successfully received a trem-cel transplant and engrafted normally. These data were presented today by Miguel-Angel Perales, MD, Chief, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center in a late-breaking poster at the 2023 Tandem Meetings in Orlando, FL. Patient 1 maintained neutrophil and platelet counts approximately five months after transplantation with trem-cel. Due to detectable measurable residual disease, Patient 1 was moved to other therapies following administration of the third dose of Mylotarg, subsequently relapsed, and remains on study for long-term follow-up. Similar to Patient 1, Patient 2 successfully received a trem-cel transplant and showed robust cell recovery with neutrophil engraftment occurring at Day 11 and platelet recovery on Day 17. Trem-cel was well tolerated in both patients, with no related and no unexpected adverse events reported. In Patient 1, neutrophil and platelet cell counts were maintained following three sequential Mylotarg doses at 0.5 mg/m2. This suggests potential protection from Mylotarg-related hematotoxicity. The only AE observed possibly related to Mylotarg through dose 3 was low grade nausea and vomiting, a known side-effect of Mylotarg. Mylotarg first-dose pharmacokinetics revealed 0.5 mg/m2 achieved Cmax and AUC parameters equivalent to 1-2 and 4-5 mg/m2 accordingly, potentially due to the decreased CD33 antigen sink. In Patient 1, CD33-negative donor hematopoiesis was enriched across hematopoietic cell types following Mylotarg administration. In addition, the CD33 deletion was observed in donor cells of myeloid and lymphoid origin which were both enriched following Mylotarg, suggesting that CD33 is expressed in early hematopoietic cells and that Mylotarg treatment enriches for edited donor cells. Interest in enrollment in VBP101 continues to be strong with a high level of investigator enthusiasm at all nine study sites. The company is moving forward with dose escalation of Mylotarg per the 3+3 dose escalation schema in the protocol. The Company is also on-track to submit an IND in the first half of 2023 for VCAR33ALLO, a CAR-T therapy using allogeneic healthy donor-derived cells, which it intends use in combination with trem-cel as a Treatment System.